Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 05, 2015 11:19 AM ET

Pharmaceuticals

Company Overview of Vet-Stem, Inc.

Company Overview

Vet-Stem, Inc. develops therapies in veterinary medicine. It develops therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in animals. The company provides laboratory services that enable veterinarians to utilize regenerative cells in animals; and autologous regenerative cells turnaround, vet to vet consultation, and cell banking services. It also offers veterinarian consultation, educational presentations, collection and shipping system, training materials, protocols and information for utilization of regenerative cell therapy, and literature references and background information services. The company serves animal own...

12860 Danielson Court

Suite B

Poway, CA 92064

United States

Founded in 2002

Phone:

858-748-2004

Fax:

858-748-2005

Key Executives for Vet-Stem, Inc.

Co-founder and Chief Executive Officer
President and Chief Commercial Officer
Co-Founder and Member of Scientific Advisory Board
Vice President of Operations
Vice President of Product Development
Compensation as of Fiscal Year 2014.

Vet-Stem, Inc. Key Developments

Aratana Therapeutics, Inc. Enters into Exclusive License Agreement with Vet-Stem, Inc., for its Novel, Allogeneic Stem Cell Therapy Technology

Aratana Therapeutics, Inc. announced it has entered into an exclusive license agreement with Vet-Stem, Inc., for its novel, allogeneic stem cell therapy technology. Under the agreement, Aratana obtains exclusive rights to commercialize Vet-Stem's allogeneic stem cells in the United States, which if approved, will be the first FDA-regulated, 'off the shelf' regenerative cell therapy for the treatment of osteoarthritis in dogs. Vet-Stem has now developed a technology platform for producing allogeneic stem cell therapies, where a single donor sample can be used to generate a large bank of doses that can be stored and used to treat multiple patients. Aratana has licensed this allogeneic therapy, which will be tested for safety and efficacy in randomized, placebo-controlled dogs with osteoarthritis and submitted to the FDA for approval. Under the terms of the agreement, Aratana will have an exclusive license to develop and commercialize products in the U.S., based upon Vet-Stem Technology for the treatment of pain and inflammation of canine osteoarthritis. Vet-Stem will continue to be responsible for the ongoing development of its allogeneic stem cell technology. Aratana will pay $500,000 upon signing of the license as a reimbursement to Vet-Stem for a portion of its past development expenses and will be responsible for funding future budgeted development. Aratana will also pay up to $4.5 million in success-based development and regulatory milestones, as well as tiered royalties upon potential commercialization of the stem cell therapy, based on potential sales. Aratana will also have the exclusive right to negotiate expansion of the agreement to include the European Union countries during the calendar year of 2014.

Vet-Stem, Inc. Signs License Agreement with Human Stem Cell Company

Vet-Stem, Inc. entered into a non-exclusive European license agreement with a human stem cell company. Under the terms of the agreement, the license provides access to the newly issued Vet-Stem patent for the extraction methods and the use of adipose-derived stem cells in prevention and treatment of diseases in the human.

Similar Private Companies By Industry

Company Name Region
Phoenix Biotechnology, Inc. United States
Rare Disease Therapeutics, Inc. United States
DemeRx, Inc. United States
Ludwig Institute for Cancer Research Ltd. United States
Greer Laboratories, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Vet-Stem, Inc., please visit www.vet-stem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.